← Eichor
Study identifier: NCT03826992 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Condition: Leukemia  ·  Sponsor: Children's Hospital Medical Center, Cincinnati

PhasePhase 1
Planned participants21
Who can joinAll sexes, 1 Year to 39 Years
Healthy volunteersNo

About this study

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Site Pulblic Contact  ·  513-636-2799  ·  cancer@cchmc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Cincinnati Children's Hospital Medical CenterCincinnati, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03826992